ASP Isotopes (ASPI) Registration Filing summary

Company overview and business model

• Operates as a development-stage advanced materials company focused on isotope enrichment technologies for use in pharmaceuticals, semiconductors, quantum computing, and nuclear fuels.

• Utilizes proprietary Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE) technologies to produce enriched isotopes such as Carbon-14, Silicon-28, and Ytterbium-176.

• Commercial production at enrichment facilities in Pretoria, South Africa began in Q1 2025, with plans for additional plants in Iceland and the U.S.

• Two operating segments: nuclear fuels (focused on HALEU and Lithium-6) and specialist isotopes for medical, semiconductor, and industrial markets.

• Plans to spin out the nuclear fuels business (Quantum Leap Energy LLC) as a separate public company in the second half of 2025, subject to approvals.

Financial performance and metrics

• As of December 31, 2024, reported cash and cash equivalents of approximately $61.9 million.

• Historical net tangible book value as of December 31, 2024 was $44.7 million, or $0.62 per share.

• After the offering, as adjusted net tangible book value would be $68.7 million, or $0.90 per share, resulting in immediate dilution of $4.46 per share to new investors at an assumed offering price of $5.36.

Use of proceeds and capital allocation

• Net proceeds from the offering will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures.

• May also use a portion of proceeds for acquisitions or investments in complementary businesses, products, or technologies, though no binding commitments exist as of the filing date.

• Pending use, proceeds may be invested in short-term, investment-grade instruments or U.S. government obligations.